Study of a Management Strategy of Functional Bowel Disordes Related to Irritable Bowel Syndrome (IBS) With a Mixture of 8 Microbiotic Strains

PiLeJe

Status

Completed

Conditions

Irritable Bowel Syndrome

Treatments

Other: Stool sampling

Dietary Supplement: Lactichoc

Study type

Interventional

Funder types

Industry

Identifiers

Pil-LACCB-017

Details and patient eligibility

About

The aim of this study is to determine the impact of a 10-day treatment with Lactichoc® on irritable bowel syndrome.

Enrollment

189 patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Having IBS symptomatology meeting the Rome IV criteria;
Having a IBS-SSS score ≥150 ;
In a state of general and mental health compatible with participation in the study ;
Agreeing to maintain their lifestyle during the study (same dietary and physical activity habits) ;
Willing to take stool samples;
Able and willing to participate in the research by complying with the protocol procedures, especially regarding the consumption of the study product;
Having electronic tools (computer, tablet...) and an internet connection, allowing him/her to fill out the self-questionnaires of the study online;
Affiliated to a social security system.

Exclusion criteria

Have a history of hypersensitivity to any of the ingredients of the study product;
Under antibiotic treatment, or having stopped it for less than 14 days;
Under dietary supplementation (prebiotics or probiotics) or having stopped it for less than one month;
Having initiated or modified a background treatment for a comorbidity for less than one month, or planning to initiate it during the study, or planning to interrupt it during the study;
Having a lifestyle incompatible with the study as determined by the investigator;
Women who are pregnant or breastfeeding or who intend to become pregnant within the next 2 months;
Planning to travel extensively during the study period or unable to be contacted in case of emergency;
Psychologically or linguistically unable to understand and sign the informed consent;
Participating in another clinical trial or on an exclusion period from a previous clinical trial;
Under legal protection (guardianship, curatorship) or deprived of their rights following an administrative or judicial decision.